Want to see GB:NFX full AI Analyst Report?
Top Page
Nuformix Plc
(LSE:NFX)
Select Model
Select Model
Rating:45Neutral
Price Target:
0.18 p
▲(12.50% Upside)
Action:Reiterated
Date:08/20/26
The score is primarily constrained by weak financial performance (no recent revenue, ongoing losses, and continued cash burn), partially offset by a debt-free balance sheet. Technicals show some near-term stabilization above shorter moving averages, but longer-term trend and momentum remain mixed. Valuation is not supportive due to negative earnings and no dividend data.
Positive Factors
Debt-free balance sheet
No debt reduces interest and refinancing risk, preserving flexibility for research and development. This is a durable balance-sheet advantage, although the benefit is moderated by the company’s small and declining asset base.
Negative Factors
No recent revenue
The absence of recent revenue indicates that the pipeline has not yet achieved meaningful commercialization. This leaves the business dependent on future clinical progress, licensing, milestones, or royalties rather than established operating income.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
No debt reduces interest and refinancing risk, preserving flexibility for research and development. This is a durable balance-sheet advantage, although the benefit is moderated by the company’s small and declining asset base.
Read all positive factors
Nuformix Plc (NFX) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£4.31M
Dividend YieldN/A
Average Volume (3M)28.87M
Price to Earnings (P/E)―
Beta (1Y)-0.10
Revenue GrowthN/A
EPS Growth93.02%
CountryUK
Employees3
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)<0.01
Shares Outstanding2,609,750,000
10 Day Avg. Volume14,006,571
30 Day Avg. Volume28,872,731
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)5.17
Price to Sales (P/S)0.00
P/FCF Ratio-6.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Nuformix Plc Business Overview & Revenue Model
Company Description
Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes in developing therapies for fibrotic diseases and cancer, primarily through the innovative strategy of drug repurposing. Its current development portfolio includes NXP...
How the Company Makes Money
Nuformix Plc’s monetization is primarily expected to come from developing its drug candidates and then generating proceeds through commercial partnering rather than large-scale in-house manufacturing and sales. Key revenue streams would typically ...
Nuformix Plc Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
52
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Mar 2023 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 50.00K | 195.55K |
| Gross Profit | -14.04K | -28.63K | -29.17K | -36.75K | 11.33K | 86.72K |
| EBITDA | -978.41K | -631.94K | -477.19K | -581.90K | -1.23M | -1.28M |
| Net Income | -998.79K | -652.59K | -3.64M | -572.98K | -1.11M | -1.25M |
Balance Sheet | ||||||
| Total Assets | 1.86M | 1.02M | 970.54K | 4.42M | 4.98M | 6.01M |
| Cash, Cash Equivalents and Short-Term Investments | 930.28K | 97.55K | 20.21K | 202.55K | 464.10K | 1.67M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 227.21K | 263.92K | 254.97K | 222.99K | 237.86K | 324.62K |
| Stockholders Equity | 1.64M | 754.93K | 715.57K | 4.20M | 4.74M | 5.69M |
Cash Flow | ||||||
| Free Cash Flow | -618.91K | -614.61K | -331.88K | -397.49K | -1.35M | -848.83K |
| Operating Cash Flow | -618.91K | -614.61K | -331.88K | -397.49K | -1.35M | -848.22K |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 33.33K | 0.00 | 43.72K |
| Financing Cash Flow | 1.45M | 691.95K | 149.54K | 189.79K | 139.98K | 1.93M |
Nuformix Plc Technical Analysis
Neutral
0.16
Price Trends
0.16
Positive
0.17
Negative
0.21
Negative
Market Momentum
<0.01
Negative
52.43
Neutral
37.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:NFX, the sentiment is Neutral. The current price of 0.16 is above the 20-day moving average (MA) of 0.15, above the 50-day MA of 0.16, and below the 200-day MA of 0.21, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 52.43 is Neutral, neither overbought nor oversold. The STOCH value of 37.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:NFX.
Nuformix Plc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £3.98M | -1.68 | -37.30% | ― | ― | 85.56% | |
46 Neutral | £5.94M | -1.52 | -52.92% | ― | 34.02% | -93.85% | |
45 Neutral | £4.31M | -3.50 | -83.53% | ― | ― | 93.02% | |
45 Neutral | £35.36M | -2.35 | -2807.75% | ― | ― | -28.29% | |
43 Neutral | £1.62M | -0.44 | -152.41% | ― | -70.77% | 60.39% | |
42 Neutral | £22.46M | -9.73 | -353.21% | 17.86% | ― | 36.67% |
* Healthcare Sector Average
GB:NFX
Nuformix Plc
0.16
0.07
72.04%
GB:TCF
Evgen Pharma
0.19
-0.05
-22.92%
GB:FUM
Futura Medical
0.21
-9.81
-97.90%
GB:IMM
ImmuPharma
4.00
-4.06
-50.37%
GB:OPTI
OptiBiotix Health
5.75
-4.50
-43.90%
GB:HEMO
HemoGenyx Pharmaceuticals Plc
502.50
-391.50
-43.79%
Nuformix Plc Corporate Events
Business Operations and StrategyProduct-Related Announcements
Nuformix Advances Inhaled Fibrosis Drug NXP002 With Positive Preclinical Data
Positive
Aug 19, 2026
Nuformix has reported positive preclinical data from an inhaled pharmacokinetic and target engagement study of NXP002, its lead inhaled therapy candidate for idiopathic and progressive pulmonary fibrosis and related interstitial lung diseases. The...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingProduct-Related Announcements
Nuformix Secures Orphan Status and Funding to Advance Inhaled IPF Therapy
Positive
May 28, 2026
Nuformix reported interim results highlighting progress on NXP002, its lead inhaled therapy candidate for idiopathic pulmonary fibrosis and other progressive fibrosing interstitial lung diseases, including securing U.S. FDA Orphan Drug Designation...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.